rs16929236

Variant names:

• chr9-126697706-A-G
• rs16929236
• NM_001174147.2:c.*1255A>G

Your query was ambiguous. Multiple possible variants found:

• chr9-126697706-A-G
• chr9-126697706-A-T

Variant summary

Our verdict is Benign. The variant received -12 ACMG points: 0P and 12B. BP4_Strong BA1

The NM_001174147.2(LMX1B):​c.*1255A>G variant causes a 3 prime UTR change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.183 in 152,242 control chromosomes in the GnomAD database, including 3,276 homozygotes. In-silico tool predicts a benign outcome for this variant. No clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar.

• Frequency:
  • Genomes: 𝑓 0.18 (3274 hom., cov: 32)
  • Exomes 𝑓: 0.12 (2 hom.)
• Consequence: LMX1B NM_001174147.2 3_prime_UTR
• Clinical Significance: Benign criteria provided, multiple submitters, no conflicts B:2
• Conservation: PhyloP100: 0.0200
• Publications: 4 publications found

Genes affected

LMX1B (HGNC:6654): (LIM homeobox transcription factor 1 beta) This gene encodes a member of LIM-homeodomain family of proteins containing two N-terminal zinc-binding LIM domains, 1 homeodomain, and a C-terminal glutamine-rich domain. It functions as a transcription factor, and is essential for the normal development of dorsal limb structures, the glomerular basement membrane, the anterior segment of the eye, and dopaminergic and serotonergic neurons. Mutations in this gene are associated with nail-patella syndrome. Alternatively spliced transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Mar 2010]

LMX1B Gene-Disease associations (from GenCC):

• nail-patella syndrome

  Inheritance: AD Classification: DEFINITIVE, STRONG, SUPPORTIVE Submitted by: ClinGen, Labcorp Genetics (formerly Invitae), Orphanet, G2P
• nail-patella-like renal disease

  Inheritance: AD Classification: SUPPORTIVE Submitted by: Orphanet

ACMG classification

Our verdict: Benign. The variant received -12 ACMG points.

• BP4: Computational evidence support a benign effect (BayesDel_noAF=-0.9).
• BA1: GnomAd4 highest subpopulation (EAS) allele frequency at 95% confidence interval = 0.338 is higher than 0.05.

Transcripts

RefSeq

Gene	Transcript	HGVSc	HGVSp	Effect	Exon rank	MANE	Protein	UniProt
LMX1B	NM_001174147.2	c.*1255A>G		3_prime_UTR_variant	Exon 8 of 8	ENST00000373474.9	NP_001167618.1
LMX1B	NM_001174146.2	c.*1255A>G		3_prime_UTR_variant	Exon 8 of 8		NP_001167617.1
LMX1B	NM_002316.4	c.*1255A>G		3_prime_UTR_variant	Exon 8 of 8		NP_002307.2

Ensembl

Gene	Transcript	HGVSc	HGVSp	Effect	Exon rank	TSL	MANE	Protein	Appris	UniProt
LMX1B	ENST00000373474.9	c.*1255A>G		3_prime_UTR_variant	Exon 8 of 8	1	NM_001174147.2	ENSP00000362573.3
LMX1B	ENST00000355497.10	c.*1255A>G		3_prime_UTR_variant	Exon 8 of 8	1		ENSP00000347684.5
LMX1B	ENST00000526117.6	c.*1255A>G		3_prime_UTR_variant	Exon 8 of 8	1		ENSP00000436930.1

Frequencies

GnomAD3 genomes AF: 0.183 AC: 27757 AN: 151974 Hom.: 3251 Cov.: 32

Gnomad AFR AF: 0.311

Gnomad AMI AF: 0.0967

Gnomad AMR AF: 0.188

Gnomad ASJ AF: 0.0680

Gnomad EAS AF: 0.351

Gnomad SAS AF: 0.104

Gnomad FIN AF: 0.148

Gnomad MID AF: 0.138

Gnomad NFE AF: 0.110

Gnomad OTH AF: 0.145

GnomAD4 exome AF: 0.120 AC: 18 AN: 150 Hom.: 2 Cov.: 0 AF XY: 0.118 AC XY: 13 AN XY: 110

African (AFR) AF: 0.00 AC: 0 AN: 2

American (AMR) AC: 0 AN: 0

Ashkenazi Jewish (ASJ) AC: 0 AN: 0

East Asian (EAS) AF: 0.500 AC: 3 AN: 6

South Asian (SAS) AF: 0.00 AC: 0 AN: 6

European-Finnish (FIN) AF: 0.214 AC: 3 AN: 14

Middle Eastern (MID) AC: 0 AN: 0

European-Non Finnish (NFE) AF: 0.0926 AC: 10 AN: 108

Other (OTH) AF: 0.143 AC: 2 AN: 14

GnomAD4 genome AF: 0.183 AC: 27819 AN: 152092 Hom.: 3274 Cov.: 32 AF XY: 0.185 AC XY: 13725 AN XY: 74362

African (AFR) AF: 0.312 AC: 12912 AN: 41434

American (AMR) AF: 0.188 AC: 2872 AN: 15292

Ashkenazi Jewish (ASJ) AF: 0.0680 AC: 236 AN: 3472

East Asian (EAS) AF: 0.351 AC: 1818 AN: 5174

South Asian (SAS) AF: 0.103 AC: 497 AN: 4816

European-Finnish (FIN) AF: 0.148 AC: 1565 AN: 10602

Middle Eastern (MID) AF: 0.141 AC: 41 AN: 290

European-Non Finnish (NFE) AF: 0.110 AC: 7486 AN: 67994

Other (OTH) AF: 0.144 AC: 304 AN: 2108

Alfa AF: 0.127 Hom.: 956

Bravo AF: 0.196

Asia WGS AF: 0.197 AC: 686 AN: 3478

ClinVar

Significance: Benign

Submissions summary: Benign:2

Revision: criteria provided, multiple submitters, no conflicts

Submissions by phenotype

not provided Benign:1

-

Breakthrough Genomics, Breakthrough Genomics

Significance: Benign

Review Status: criteria provided, single submitter

Collection Method: not provided

- -

Nail-patella syndrome Benign:1

Jan 13, 2018

Illumina Laboratory Services, Illumina

Significance: Benign

Review Status: criteria provided, single submitter

Collection Method: clinical testing

This variant was observed in the ICSL laboratory as part of a predisposition screen in an ostensibly healthy population. It had not been previously curated by ICSL or reported in the Human Gene Mutation Database (HGMD: prior to June 1st, 2018), and was therefore a candidate for classification through an automated scoring system. Utilizing variant allele frequency, disease prevalence and penetrance estimates, and inheritance mode, an automated score was calculated to assess if this variant is too frequent to cause the disease. Based on the score and internal cut-off values, a variant classified as benign is not then subjected to further curation. The score for this variant resulted in a classification of benign for this disease. -

Computational scores

Source: dbNSFP v4.3

Name	Calibrated prediction	Score	Prediction
BayesDel_noAF	Benign	-0.90
CADD	Benign	2.8
DANN	Benign	0.41
PhyloP100		0.020
Mutation Taster		=100/0	polymorphism (auto)

Splicing

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

Other links and lift over

dbSNP: rs16929236; hg19: chr9-129459985;